← SynDRA
AMIFAMPRIDINE
SynDRA canonical compound SYN0005397 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Mechanism of action | potassium channel blocker |
|---|
| Indication | Lambert-Eaton myasthenic syndrome (LEMS) |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
- KCNA1
- KCNA10
- KCNH1
- KCNH2
- KCNH3
- KCNH4
- KCNH5
- KCNH6
- KCNH7
- KCNH8
- KCNQ1
- KCNQ2
Mechanisms of action (all sources)
- KCNQ1 BLOCKER
- Voltage-gated potassium channel blocker
- KCND3 BLOCKER
- KCNH2 BLOCKER
- KCNA2 BLOCKER
- KCNA1 BLOCKER
- KCNQ2 BLOCKER
- KCNQ3 BLOCKER
- KCNA7 BLOCKER
- KCNQ5 BLOCKER
- KCNQ4 BLOCKER
- KCNH1 BLOCKER
Drug classes
- Potassium Channel Antagonists
- Cardiovascular Agents
- Membrane Transport Modulators
- Neuromuscular Agents
- Peripheral Nervous System Agents
- Potassium Channel Blockers
- Potassium Channel Blocker
ATC classes
- N07X · OTHER NERVOUS SYSTEM DRUGS
Cross-references
Synonyms
- firdapse
- amifampridin
- amifampridine phosphate
- DAP
- 3,4-DAP
- Amifampridina
- 3,4-diammoniopyridinium
- Dynamine
- Pyridine-3,4-diamine
- 4-DAP
- NSC-521760
- Ruzurgi
- 3,4-DIAMINOPYRIDINE
- pyridine-3,4-diamine
- 3,4-Pyridinediamine
- Firdapse
- Diamino-3,4 pyridine
- 4,5-Diaminopyridine
- SC10
- Zenas
- UNII-RU4S6E2G0J
- EINECS 200-220-9
- NSC 521760
- BRN 0110232
- RU4S6E2G0J
- OYTKINVCDFNREN-UHFFFAOYSA-N
- WT559
- NCGC00167560-01
- SMR000752913
- 3,4-Diaminopyridine
- Pyridine, 3,4-diamino-
- dap
- amifampridina
- DTXCID4026715
- 5-22-11-00266 (Beilstein Handbook Reference)
- NSC521760
- amifampridinum
- RefChem:54154
Reported adverse events
- Abdominal pain
- Asthenia
- Back pain
- Bronchitis
- Cataract
- Constipation
- Dizziness
- Fall
- Headache
- Hypersensitivity
- Hypertension
- Lymphadenopathy
Look up AMIFAMPRIDINE in the interactive SynDRA portal →